Regenxbio CEO Ken Mills leaves post

  • After around 15 years in the position
  • Praise and thanks for Mills
  • Curran Simpson taking over
  • Mills will remain as Chairman at Regenxbio
  • Mills said 108 words

(exechange) — Rockville, Maryland, June 12, 2024 — Ken Mills, chief executive of Regenxbio, leaves his position. As announced by Regenxbio Inc. in a news release on Wednesday, June 12, 2024, Kenneth T. (Ken) Mills leaves his post as chief executive officer at the clinical-stage biotechnology company, after around 15 years in the role, effective July 1, 2024.

It is the end of an era.

Generally speaking, it raises questions when a CEO leaves his post at short notice.

Ken Mills’s duties as CEO will be taken over by Curran Simpson, currently Chief Operating Officer at Regenxbio Inc.

“Now is the right time”

The management change is explained as follows. Mills stated: “As we advance our pivotal stage clinical trials, approach commercialization and prepare for our next chapter, now is the right time to transition leadership.”

Mills will remain as Chairman at Regenxbio

Regenxbio stated: “Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman.”

Share price decline since June 2019

The announcement follows a decline in Regenxbio Inc.’s share price of 69% since June 2019.

In the position of CEO since 2009

Ken Mills became CEO of the Company in 2009.

Kenneth T. Mills has been the Company’s President, Chief Executive Officer and Director since March 2009.

Mills was with FOXKISER, most recently as a Partner, from January 2007 to January 2015.

Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a life sciences company, from January 2004 to December 2006 and was part of the original management team that established the company’s operations and financing strategy.

From March 1997 to December 2003, Mills was employed at IGEN International, Inc., a biotechnology company, where he served as Director of Business Development up through the company’s acquisition by Roche.

Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology.

108 words by Ken Mills

In the release announcing his departure as CEO of Regenxbio Inc., Ken Mills received praise and thanks.

In the release announcing his departure as CEO, Ken Mills said 108 words.

“Excited”

Ken Mills stated: “Leading Regenxbio since our founding in 2009 has been a privilege. We have built the Company into a leader in gene therapy medicines with exciting products progressing through late-stage developments. As we advance our pivotal stage clinical trials, approach commercialization and prepare for our next chapter, now is the right time to transition leadership. Curran and I have worked closely together over the last nine years, and I am confident he brings the R&D, operational, and industry expertise to build on our momentum. I am enthusiastic about the future of Regenxbio and excited to continue partnering with Curran and working alongside the Board in my role as Chairman.”

The above text is an excerpt from the exechange report 25.2024 ($), publication date June 17, 2024.